C-Type Natriuretic Peptide (CNP) (1-22)，人 TFA，通过结合利钠肽受体 B (NPR-B) 发挥其主要生物学效应，NPR-B 是一种膜结合鸟苷酸环化酶受体，可产生环磷酸鸟苷 (cGMP) .
C-Type Natriuretic Peptide (CNP) (1-22), human TFA, exerts its main biological effects by binding to natriuretic peptide receptor B (NPR-B), a membrane-bound guanylyl cyclase receptor that produces cyclic guanosine monophosphate (cGMP). C-Type Natriuretic Peptide (CNP) is a selective agonist of natriuretic peptide receptors NPR-B and C (Kds = 7, and 10.8 pM) [1].
C-Type Natriuretic Peptide (CNP) (1-22), significantly promoted longitudinal bone growth in an organ culture experiment using tibiae from fetal mice [2]. C-Type Natriuretic Peptide (CNP) (1-22) in vivo administration might attenuate cardiac remodeling after myocardial infarction (MI) through its antifibrotic and antihypertrophic action [3]. NPR-B-mediated cGMP production after CNP administration specifically acted on the pylorus, colon, and rectum and contributed to gastric emptying [1].
参考文献:
[1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9.
[2]. Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, Nakao K (1998) Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 273:11 695-11 700
[3]. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, Kangawa K. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. 2005.J Am Coll Cardiol 45:608-616
C 型钠尿肽 (CNP) (1-22)，人 TFA，通过与钠尿肽受体 B (NPR-B) 结合发挥其主要生物学作用，NPR-B 是一种膜结合鸟苷酸环化酶受体，可产生环磷酸鸟苷（cGMP）。 C-Type Natriuretic Peptide (CNP) 是利钠肽受体 NPR-B 和 C（Kds = 7 和 10.8 pM）的选择性激动剂[1]。
C 型钠尿肽 (CNP) (1-22)，在使用胎鼠胫骨的器官培养实验中显着促进纵向骨生长 [2]。 C 型钠尿肽 (CNP) (1-22) 体内给药可能通过其抗纤维化和抗肥大作用减弱心肌梗死 (MI) 后的心脏重塑[3]。 CNP 给药后 NPR-B 介导的 cGMP 产生特异性作用于幽门、结肠和直肠，并有助于胃排空[1]。
| Animal experiment [2]: | |
|
Animal models |
Four-week-old female ddY mice |
|
Preparation Method |
Mice were separated into four groups: the untreated (baseline) group, the 2 mg/kg C-Type Natriuretic Peptide (CNP) group, the 1 mg/kg C-Type Natriuretic Peptide (CNP) group, and the vehicle (normal saline) group. C-Type Natriuretic Peptide (CNP) and vehicle were administered intravenously. |
|
Dosage form |
Intravenously injection, 1 or 2 mg/kg |
|
Applications |
In the pylorus and rectum, after 2 mg/kg C-Type Natriuretic Peptide (CNP) was administered, cGMP production was remarkably increased as early as 1 minute compared with that after 1 mg/kg C-Type Natriuretic Peptide (CNP) was administered |
|
参考文献: [1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9. | |
动态评分
0.0